NANETS consensus guidelines for the diagnosis of neuroendocrine tumor

Pancreas

Volumn 39, Issue 6, 2010, Pages 713-734

  Vinik, Aaron I ^a   Woltering, Eugene A ^b   Warner, Richard R P ^c   Caplin, Martyn ^d   O'Dorisio, Thomas M ^e   Wiseman, Gregory A ^f   Coppola, Domenico ^g   Go, Vay Liang W ^h  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f MAYO CLINIC   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; C PEPTIDE; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CHROMOGRANIN; CORTICOTROPIN; DOPAMINE; GASTRIN; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HISTAMINE; KALLIKREIN; KININ; MOTILIN; NEUROKININ A; NEURON SPECIFIC ENOLASE; NEUROPEPTIDE K; NEUROTENSIN; PANCREAS POLYPEPTIDE; PROSTAGLANDIN; SEROTONIN; SOMATOMEDIN B; SOMATOSTATIN; SUBSTANCE P; SYNAPTOPHYSIN; TUMOR MARKER; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL PAIN; ACROMEGALY; BRONCHOSPASM; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CUSHING SYNDROME; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DYSPEPSIA; ECHOGRAPHY; ENDOSCOPY; ENZYME ACTIVATION; EPILEPSY; FLUSHING; GASTRINOMA; GASTROINTESTINAL RADIOGRAPHY; GLUCAGONOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INSULINOMA; INTESTINE; IRRITABLE COLON; LAPAROTOMY; MASTOCYTOSIS; MEDICAL SOCIETY; MICROSCOPY; MIDGUT; MOLECULAR GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PELLAGRA; PEPTIC ULCER; PHEOCHROMOCYTOMA; POSTGASTRECTOMY SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; RADIOIMMUNOASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; SOMATOSTATINOMA; STEATORRHEA; THYROID MEDULLARY CARCINOMA; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; ULCER; VIPOMA; WEIGHT REDUCTION; WHEEZING;

CHROMOGRANIN A; HUMANS; HYDROXYINDOLEACETIC ACID; NEUROENDOCRINE TUMORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955226626     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ebaffd     Document Type: Review

References (214)

1. Massironi S, Sciola V, Peracchi M, et al. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14:5377-5384.
2. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(suppl 1):33-38.
3. Lamberts SWJ, Hofland LJ, Nobels FRE. Neuroendocrine tumor markers. Front Neuroendocrinol. 2001;22:309-339.
4. Vinik A, O'Dorisio T, Woltering E, et al. Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. 1st ed. Interscience Institute; 2006.
5. Vinik AI. Carcinoid syndrome. Diffuse hormonal systems and endocrine tumor syndromes. 2008.
6. Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81:41-48.
7. Ahlman H, Dalström A, Grönstad K, et al. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. Ann Surg. 1985;201:81-86.
8. Kaplan EL, Jaffe BM, Peskin GW. A new provocative test for the diagnosis of the carcinoid syndrome. Am J Surg. 1972;123:173-179.
9. Vinik AI, Gonin J, England BG, et al. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog. J Clin Endocrinol Metab. 1990;70:1702-1709.
10. Conlon JM. The glucagon-like polypeptidesVorder out of chaos? Diabetologia. 1980;18:85-88.
11. Cunningham JL, Janson ET, Agarwal S, et al. Tachykinins in endocrine tumors and the carcinoid syndrome. Eur J Endocrinol. 2008;159:275-282.
12. Won JG, Tseng HS, Yang AH, et al. Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf). 2006;65:566-578.
13. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511.
14. Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168-172.
15. Norton JA, Melcher ML, Gibril F, et al. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136:1267-1274.
16. Ruszniewski P, Delle FG, Cadiot G, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006;84:158-164.
17. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15: 966-973.
18. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685-690.
19. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: SEER 17 Regs Nov 2006 sub (1973-2004), ed released April 2006, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistic Branch. 2006. National Cancer Institute. Available at: www.seer.cancer.gov. Accessed May 27, 2010.
20. Wang GG, Yao JC, Worah S, et al. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol. 2005;18:1079-1087.
21. Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol. 2001;158: 1803-1808.
22. Choi IS, Estecio MR, Nagano Y, et al. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007;20: 802-810.
23. Goebel SU, Serrano J, Yu F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85: 1470-1483. (Pubitemid 29152818)
24. Bernini GP, Moretti A, Ferdeghini M, et al. A new human chromogranin FA- immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer. 2001;84:636-642.
25. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004;60:644-652.
26. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865.
27. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J. 1995;71:542-545.
28. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr. 1985;42: 639-643.
29. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135: 1469-1492.
30. Kloppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the tract. Best Pract Res Clin Gastroenterol. 2005;19:507-517.
31. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-781.
32. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196-211.
33. O'Toole D, Salazar R, Falconi M, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006;84:189-195.
34. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113: 1807-1843.
35. Gibril F, Schumann M, Pace A, et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004;83:43-83.
36. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19: 783-798.
37. de Herder WW, Niederle B, Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183-188.
38. Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222-3226.
39. Quinkler M, Strelow F, Pirlich M, et al. Assessment of suspected insulinoma by 48-hour fasting test: a retrospective monocentric study of 23 cases. Horm Metab Res. 2007;39:507-510.
40. Kann PH, Balakina E, Ivan D, et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13:1195-1202.
41. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000;79:379-411.
42. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173-182.
43. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295-330.
44. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454-463.
45. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331-364.
46. Arnold R. Diagnosis and differential diagnosis of hypergastrinemia. Wien Klin Wochenschr. 2007;119:564-569.
47. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther. 2001;15: 1555-1561.
48. Agreus L, Storskrubb T, Aro P, et al. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol. 2009;44:564-570.
49. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4-19.
50. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosisVa prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore). 2001;80:189-222.
51. Goldman JA, Blanton WP, Hay DW, et al. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009;7: 600-602.
52. Thom AK, Norton JA, Axiotis CA, et al. Location, incidence, and malignant potential of duodenal gastrinomas. Surgery. 1991;110: 1086-1091.
53. Jensen R, Gardner J. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, et al, eds. The Pancreas: Biology, Pathobiology and Disease. 2nd ed. New York: Raven Press Publishing Co; 1993: 931-978.
54. Thakker RV. Multiple endocrine neoplasia. Horm Res. 2001; 56(suppl 1):67-72.
55. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005;19:675-697.
56. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635-644.
57. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108: 1637-1649.
58. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615-630.
59. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol. 1998;16:1040-1053.
60. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477-488.
61. Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery. 1987;102:958-966.
62. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247: 501-510.
63. Jensen RT. Endocrine neoplasms of the pancreas. In: Yamada T, Alpers DH, Kalloo AN, et al, eds. Textbook of Gastroenterology. 5th ed. Oxford, England: Wiley-Blackwell; 2009: 1875-1920.
64. Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol. 2007;24:330-337.
65. van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531-537.
66. Montenegro F, Lawrence GD, Macon W, et al. Metastatic glucagonoma. improvement after surgical debulking. Am J Surg. 1980;139:424-427.
67. Vinik AI. Glucagonoma syndrome. Diffuse hormonal systems and endocrine tumor syndromes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. Inglewood, CA: Inter Science Institute; 2004.
68. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52:1259-1265.
69. Vale W, Rivier C, Brown M. Regulatory peptides of the hypothalamus. Annu Rev Physiol. 1977;39:473-527.
70. Creutzfeldt W, Arnold R. Somatostatin and the stomach: exocrine and endocrine aspects. Metabolism. 1978;27:1309-1315.
71. Ganda OP, Weir GC, Soeldner JS, et al. BSomatostatinoma[: a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med. 1977;296:963-967.
72. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979;301:285-292.
73. Larsson LI, Hirsch MA, Holst JJ, et al. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet. 1977;1: 666-668.
74. Crain EL Jr, Thorn GW. Functioning pancreatic islet cell adenomas; a review of the literature and presentation of two new differential tests. Medicine (Baltimore). 1949;28:427-447.
75. Fisher RS, Rock E, Levin G, et al. Effects of somatostatin on gallbladder emptying. Gastroenterology. 1987;92:885-890.
76. Axelrod L, Bush MA, Hirsch HJ, et al. Malignant somatostatinoma: clinical features and metabolic studies. J Clin Endocrinol Metab. 1981;52:886-896.
77. Penman E, Wass JA, Besser GM, et al. Somatostatin secretion by lung and thymic tumours. Clin Endocrinol (Oxf ). 1980;13:613-620.
78. Boden G, Baile CA, McLaughlin CL, et al. Effects of starvation and obesity on somatostatin, insulin, and glucagon release from an isolated perfused organ system. Am J Physiol. 1981;241:E215-E220.
79. Creutzfeldt W, Lankisch PG, Folsch UR. Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration [author's translation]. Dtsch Med Wochenschr. 1975;100:1135-1138.
80. Schwartz TW. Atropine suppression test for pancreatic polypeptide. Lancet. 1978;2:43-44.
81. Bloom SR, Mortimer CH, Thorner MO, et al. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974;2:1106-1109.
82. Vinik AI, Shapiro B, Thompson NW. Plasma gut hormone levels in 37 patients with pheochromocytomas. World J Surg. 1986;10:593-604.
83. Bhathena S, Higgins G, Recant L. Glucagonoma and Glucagonoma Syndrome. New York: Elsevier; 1981:413.
84. Vinik AI, Delbridge L, Moattari R, et al. Transhepatic portal vein catheterization for localization of insulinomas: a ten-year experience. Surgery. 1991;109:1-11.
85. Jensen RT, Gardner JD, Raufman JP, et al. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med. 1983;98:59-75.
86. Vinik AI, Levitt NS, Pimstone BL, et al. Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics. J Clin Endocrinol Metab. 1981;52: 330-337.
87. Sano T, Kagawa N, Hizawa K. Demonstration of somatostatin production in medullary carcinoma of the thyroid. Jpn J Cancer Res. 1980;10:221.
88. Saito S, Saito H, Matsumura M, et al. Molecular heterogeneity and biological activity of immunoreactive somatostatin in medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1981;53: 1117-1122.
89. Roos BA, Lindall AW, Ells J, et al. Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. J Clin Endocrinol Metab. 1981;52: 187-194.
90. Ghose RR, Gupta SK. Oat cell carcinoma of bronchus presenting with somatostatinoma syndrome. Thorax. 1981;36:550-551.
91. Jackson J, Raju U, Janakivamon N. Metastatic pulmonary somatostatinoma presenting with diabetic ketoacidosis: clinical biochemical and morphologic characterization. Clin Res. 1986;34:196A.
92. Berelowitz M, Szabo M, Barowsky HW, et al. Somatostatin-like immunoactivity and biological activity is present in a human pheochromocytoma. J Clin Endocrinol Metab. 1983;56:134-138.
93. Samols E, Weir GC, Ramseur R, et al. Modulation of pancreatic somatostatin by adrenergic and cholinergic agonism and by hyper- and hypoglycemic sulfonamides. Metabolism. 1978;27:1219-1221.
94. Pipeleers D, Couturier E, GeptsW, et al. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab. 1983;56:1236-1242.
95. Moayedoddin B, Booya F, Wermers RA, et al. Spectrum of malignant somatostatin-producing neuroendocrine tumors. Endocr Pract. 2006;12:394-400.
96. Tanaka S, Yamasaki S, Matsushita H, et al. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int. 2000;50:146-152.
97. Gola M, Doga M, Bonadonna S, et al. Neuroendocrine tumors secreting growth hormone-releasing hormone: pathophysiological and clinical aspects. Pituitary. 2006;9:221-229.
98. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with the Zollinger-Ellison syndrome. N Engl J Med. 1986;315:1-5.
99. Mao C, Carter P, Schaefer P, et al. Malignant islet cell tumor associated with hypercalcemia. Surgery. 1995;117:37-40.
100. Plockinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology. 2004;80(suppl 1):35-38.
101. Gullo L, Migliori M, Falconi M, et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;98:2435-2439.
102. Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38:876-889.
103. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
104. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:33-41.
105. Oberg K, Eriksson B. Best Practice & Research Clinical Endocrinology Metabolism. Oxford, England: Elsevier, Ltd; 2007.
106. Ardill JE. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann Clin Biochem. 2008;45:539-559.
107. Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet. 2005;366:665-675.
108. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002;4:62-72.
109. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-1466.
110. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006;1073: 30-37.
111. de Krijger RR, Petri BJ, van Nederveen FH, et al. Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci. 2006;1073:166-176.
112. Ludwig AD, Feig DI, Brandt ML, et al. Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am J Surg. 2007;194:792-796.
113. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91:827-836.
114. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63:5615-5621.
115. Bryant J, Farmer J, Kessler LJ, et al. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95:1196-1204.
116. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505-4509.
117. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92:779-786.
118. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818.
119. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427-1434.
120. Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340:1872-1879.
121. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88:553-558.
122. Lenders JW, Willemsen JJ, Eisenhofer G, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem. 2007;53:352-354.
123. Grossman A, Pacak K, Sawka A, et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci. 2006;1073:332-347.
124. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88: 2656-2666.
125. Guller U, Turek J, Eubanks S, et al. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg. 2006;243:102-107.
126. Giovanella L, Squin N, Ghelfo A, et al. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging. 2006;50:344-347.
127. Bilek R, Safarik L, Ciprova V, et al. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res. 2008;57(suppl 1):S171-S179.
128. Klein RD, Lloyd RV, Young WF. Hereditary Paraganglioma-Pheochromocytoma Syndromes. Gene Rev. 2008.
129. Algeciras-Schimnich A, Preissner CM, Young WF Jr, et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab. 2008;93:91-95.
130. Young WF Jr. Paragangliomas: clinical overview. Ann N Y Acad Sci. 2006;1073:21-29.
131. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450-455.
132. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab. 2000;85: 919-922.
133. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
134. Etit D, Faquin WC, Gaz R, et al. Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: a study of 42 cases. Arch Pathol Lab Med. 2008;132:1767-1773.
135. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:941-953.
136. Scheuba C, Kaserer K, Moritz A, et al. Sporadic hypercalcitoninemia: clinical and therapeutic consequences. Endocr Relat Cancer. 2009;16:243-253.
137. Colombo P, Locatelli F, Travaglini P. Useful and limits of the biochemical markers for the diagnosis of thyroid carcinoma [in Italian]. Ann Ital Chir. 2006;77:209-214.
138. Schley E, Shin S, Nakave AA, et al. Symptomatic isolated C-cell hyperplasia: masquerading as carcinoid syndrome. Pancreas. 2009 submitted.
139. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999;54:397-438.
140. Piecha G, Chudek J, Wiecek A. Multiple endocrine neoplasia type 1. Eur J Intern Med. 2008;19:99-103.
141. Perry R. Multiple endocrine neoplasia type 1 and MEN II. Diffuse hormonal systems and endocrine tumor syndromes. 2006.
142. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671.
143. Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol. 2004;5:315-325.
144. Fialkowski EA, DeBenedetti MK, Moley JF, et al. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg. 2008;43:188-190.
145. Raue F, Frank-Raue K. Multiple endocrine neoplasia type 2: 2007 update. Horm Res. 2007;68(suppl 5):101-104.
146. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
147. Nobels FR, Kwekkeboom DJ, Bouillon R, et al. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest. 1998;28:431-440.
148. Stridsberg M, Eriksson B, Fellstrom B, et al. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept. 2007;139:80-83.
149. Takiyyuddin MA, Cervenka JH, Hsiao RJ, et al. Storage and release in hypertension. Hypertension. 1990;15:237-246.
150. Oberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med. 1997;70:501-508.
151. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622-2628.
152. Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14:473-482.
153. Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest. 2004;27:6-11.
154. Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14:780-785.
155. Stronge RL, Turner GB, Johnston BT, et al. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours. Ann Clin Biochem. 2008;45:560-566.
156. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11:264-271.
157. Turner GB, Johnston BT, McCance DR, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006;55:1586-1591.
158. Lipton A, Costa L, Ali S, et al. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 2001;28:54-59.
159. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59-69.
160. Roberts WC. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol. 1997;80:251-256.
161. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90:1224-1228.
162. Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102:938-942.
163. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21:43-68.
164. Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med. 2000;41:1646-1656.
165. Semelka RC, Custodio CM, Cem BN, et al. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging. 2000;11:141-148.
166. Pamuklar E, Semelka RC. MR imaging of the pancreas. Magn Reson Imaging Clin N Am. 2005;13:313-330.
167. Kelekis NL, Semelka RC. MRI of pancreatic tumors. Eur Radiol. 1997;7:875-886.
168. Dromain C, de BT, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol. 2003;180:121-128.
169. Debray MP, Geoffroy O, Laissy JP, et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol. 2001;74:1065-1070.
170. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496-506.
171. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90:3392-3400.
172. Noone TC, Hosey J, Firat Z, et al. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195-211.
173. Kloppel G, Couvelard A, Perren A, et al. ENETS guidelines for the standards of care in patients with neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2008 Dec 5. [Epub ahead of print]
174. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:213-227.
175. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis. 2004;36(suppl 1):S106-S120.
176. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:69-85.
177. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773.
178. McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:177-193.
179. Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25-29.
180. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123:269-273.
181. Strader D, Doppman J, Orbuch M, et al. Functional localization of pancreatic endocrine tumors. In: Mignon M, Jensen RT, eds. In Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel, Switzerland: Karger Publishing Co; 1995:282-297.
182. Norton JA. Surgical treatment of islet cell tumors with special emphasis on operative tumors. In: Mignon M, Jensen RT, eds. In Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Basel, Switzerland: S. Karger; 1995: 309-332.
183. Shin LK, Brant-Zawadzki G, Kamaya A, et al. Intraoperative ultrasound of the pancreas. Ultrasound Q. 2009;25:39-48.
184. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
185. Eriksson B, Orlefors H, Oberg K, et al. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:311-324.
186. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin
187. Sundin A, Vullierme MP, Kaltsas G, et al. ENETS guidelines for the standards of care in patients with neuroendocrine tumours: radiological examinations in patients with neuroendocrine tumours. Neuroendocrinology. 2009;90:167-183.
188. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci. 1994;733:416-424.
189. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26-34.
190. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997;112:335-347.
191. Berna M, Jensen R. Use of radiolabeled somatostatin receptor analogues in diagnosis of gastrointestinal neuroendocrine tumors. In: Modlin IM, Oberg K, eds. A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Hanover: Felstein C.C.C.P.; 2007:328-339.
192. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539-553.
193. Hellman P, Hennings J, Akerstrom G, et al. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg. 2005;92:1508-1512.
194. Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998;124:1153-1159.
195. Langer P, Kann PH, Fendrich V, et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg. 2004;28:1317-1322.
196. Manfredi S, Pagenault M, de Lajarte-Thirouard AS, et al. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol. 2007;19:1021-1025.
197. Gibril F, Doppman JL, Chang R, et al. Metastatic gastrinomas: localization with selective arterial injection of secretin. Radiology. 1996;198:77-84.
198. Frucht H, Norton JA, London JF, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. Gastroenterology. 1990;99:1622-1627.
199. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg. 1992;215:8-18.
200. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239:617-625.
201. Sugg SL, Norton JA, Fraker DL, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993;218:138-144.
202. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004;25:568-580.
203. Lumachi F, Tregnaghi A, Zucchetta P, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006;27:583-587.
204. van der HE, de Herder WW, Bruining HA, et al. [(123)I] metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
205. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69:181-188.
206. Mackenzie IS, Gurnell M, Balan KK, et al. The use of 18-fluoro- dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol. 2007;157:533-537.
207. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88: 4083-4087.
208. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PETVinitial results. Radiology. 2002;222:507-512.
209. Timmers HJ, Hadi M, Carrasquillo JA, et al. The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48: 1599-1606.
210. Shulkin BL, Koeppe RA, Francis IR, et al. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology. 1993;186: 711-715.
211. Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35-41.
212. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269.
213. Wild D, Macke H, Christ E, et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
214. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.